Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine

Journal of Drug Targeting

Volumn 17, Issue 8, 2009, Pages 586-598

  Arias, José L ^a   Reddy, L Harivardhan ^b   Couvreur, Patrick ^b  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Antitumor activity; biodegradable polymers; colloidal drug delivery systems; controlled release; cytotoxicity; immunohistochemistry; poly(alkylcyanoacrylates)

Indexed keywords

GEMCITABINE; MONOMER; NANOPARTICLE; PLACEBO; POLY(OCTYLCYANOACRYLATE); SURFACTANT; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; CYANOACRYLATE DERIVATIVE; CYANOACRYLIC ACID OCTYL ESTER; DEOXYCYTIDINE; DRUG CARRIER; DRUG DERIVATIVE; POLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ADSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PH; POLYMERIZATION; PRIORITY JOURNAL; SLOW DRUG RELEASE; SUBCUTANEOUS TISSUE TUMOR; TREATMENT RESPONSE; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; DBA MOUSE; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA L 1210;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CYANOACRYLATES; DEOXYCYTIDINE; DRUG CARRIERS; HYDROGEN-ION CONCENTRATION; INJECTIONS, INTRAVENOUS; LEUKEMIA L1210; MICE; MICE, INBRED DBA; NANOPARTICLES; POLYMERS;

EID: 70350443227     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860903105739     Document Type: Article

References (43)

1. Adamson AW, Gast AP. (1997). The solid-liquid interface-contact angle. In: Physical Chemistry of Surfaces (6th ed., pp. 347-389). New York: John Wiley & Sons.
2. Alyaudtin RN, Reichel A, Lobenberg R, Ramge P, Kreuter J, Begley DJ. (2001). Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J Drug Target, 9, 209-221. (Pubitemid 32776368)
3. Arias JL. (2008). Novel strategies to improve the anticancer action of 5-fluorouracil by using drug delivery systems. Molecules, 13, 2340-2369.
4. Arias JL, Gallardo V, Gómez-Lopera SA, Plaza RC, Delgado AV. (2001). Synthesis and characterization of poly(ethyl-2-cyanoacrylate) nanoparticles with a magnetic core. J Control Release, 77, 309-321. (Pubitemid 33145482)
5. Arias JL, Gallardo V, Gómez-Lopera SA, Delgado AV. (2005). Loading of 5-fluorouracil to poly(ethyl-2-cyanoacrylate) nanoparticles with a magnetic core. J Biomed Nanotech, 1, 214-223.
6. Arias JL, Gallardo V, Ruiz MA, Delgado AV. (2007a). Ftorafur loading and controlled release from poly(ethyl-2-cyanoacrylate) and poly(butylcyanoacrylate) nanospheres. Int J Pharm, 337, 282-290. (Pubitemid 46756034)
7. Arias JL, López-Viota M, Ruiz MA, López-Viota J, Delgado AV. (2007b). Development of carbonyl iron/ethylcellulose core/ shell nanoparticles for biomedical applications. Int J Pharm, 339, 237-245. (Pubitemid 46977602)
8. Arias JL, Ruiz MA, López-Viota M, Delgado AV. (2008a). Poly(alkylcyanoacrylate) colloidal particles as vehicles for antitumour drug delivery: a comparative study. Colloids Surf B: Biointerfaces, 62, 64-70. (Pubitemid 351179240)
9. Arias JL, Reddy LH, Couvreur P. (2008b). Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting. Langmuir, 24, 7512-7519.
10. Barraud L, Merle P, Soma E, Lefrançois L, Guerret S, Chevallier M, Dubernet C, Couvreur P, Trépo C, Vitvitski L. (2005). Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J Hepatol, 42, 736-743.
11. Bouffard DY, Laliberté J, Momparler RL. (1993). Kinetic studies on 2′,2′-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol, 45, 1857-1861. (Pubitemid 23150977)
12. Brasseur F, Couvreur P, Kante B, Deckers-Passau L, Roland M, Deckers C, Speiser P. (1980). Actinomycin D adsorbed on polymethylcyanoacrylate nanoparticles: increased efficiency against an experimental tumor. Eur J Cancer, 16, 1441-1445. (Pubitemid 11226639)
13. Brigger I, Morizet J, Laudani L, Aubert G, Appel M, Velasco V, Terrier- Lacombe MJ, Desmaële D, d'Angelo J, Couvreur P, Vassal G. (2004). Negative preclinical results with stealth® nanospheresencapsulated doxorubicin in an orthotopic murine brain tumor model. J Control Release, 100, 29-40. (Pubitemid 39445983)
14. Cavallaro G, Fresta M, Giammona G, Puglisi G, Villari A. (1994). Entrapment of β-lactams antibiotics in polyethylcy noacrylate nanoparticles: studies on the possible in vivo application of this colloidal delivery system. Int J Pharm, 111, 31-41.
15. Couvreur P, Kante B, Roland M, Guiot P, Baudhuin P, Speiser P. (1979). Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparations, morphological and sorptive properties. J Pharm Pharmacol, 31, 331-332. (Pubitemid 9207599)
16. Chiannilkulchai N, Driouich Z, Benoit JP, Parodi AL, Couvreur P. (1989). Doxorubicin-loaded nanoparticles: increased efficiency in murine hepatic metastases. Select Cancer Ther, 5, 1-11. (Pubitemid 19173568)
17. Cuvier C, Roblot-Treupel L, Millot JM, Lizard G, Chevillard S, Maufait M, Couvreur P, Poupon MF. (1992). Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem Pharmacol, 44, 509-517.
18. Decout A, Dubernet C, Henry-Toulme N. (1996). Mechanism of doxorubicin release from polymeric particles: an interfacial transfer limited process affected by serum proteins. J Colloid Interface Sci, 181, 99-107. (Pubitemid 26236744)
19. Fang C, Shi B, Pei YY, Hong MH, Wu J, Chen HZ. (2006). In vivo tumor targeting of tumor necrosis factor-α-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur J Pharm Sci, 27, 27-36. (Pubitemid 41728252)
20. Gelperina SE, Khalansky AS, Skidan IN, Smirnova ZS, Bobruskin AI, Severin SE, Turowski B, Zanella FE, Kreuter J. (2002). Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol Lett, 126, 131-141. (Pubitemid 34075270)
21. Henry-Toulmé N, Decout A, Lalanne J, Nemati F, Dubernet C, Dufourcq J. (1994). Probing the interaction of the anticancer drug doxorubicin with polymeric nanoparticles using fluorescence spectroscopy. J Colloid Interface Sci, 162, 236-243.
22. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB. (1990). Evaluation of the antitumor activity of gemcitabine (2′,2′- difluoro-2′-deoxycytidine). Cancer Res, 50, 4417-4422. (Pubitemid 20225688)
23. Hu YP, Jarillon S, Dubernet C, Couvreur P, Robert J. (1996). On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance. Cancer Chemother Pharmacol, 37, 556-560. (Pubitemid 26080153)
24. Ibrahim A, Couvreur P, Roland M, Speiser P. (1983). New magnetic drug carrier. J Pharm Pharmacol, 35, 59-61.
25. Lherm C, Müller RH, Puisieux F, Couvreur P. (1992). Alkylcyanoacrylates drug carriers: II. Cytotoxicity of cyanoacrylate nanoparticles with different alkyl chain length. Int J Pharm, 84, 13-22.
26. Liu S, Edgerton SM, Moore DH, Thor AD. (2001). Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res, 7, 1716-1723. (Pubitemid 32708640)
27. Matsuda A, Sasaki T. (2004). Antitumor activity of sugar-modified cytosine nucleosides. Cancer Sci, 95, 105-111. (Pubitemid 38404309)
28. Merle P, Si-Ahmed S, Habersetzer F, Abergel A, Taieb J, Bonyhay L, Constantini D, Dufour-Lamartinie J, Trépo C. (2006). Phase 1 study of intra-arterial hepatic (IAH) delivery of doxorubicintransdrug ® (DT) for patients with advanced hepatocellular carcinoma (HCC). J Clin Virol, 36, S179.
29. Müller RH, Lherm C, Herbort J, Blunk T, Couvreur P. (1992). Alkylcyanoacrylate drug carriers: I. Physicochemical characterization of nanoparticles with different alkyl chain length. Int J Pharm, 84, 1-11.
30. O'Brien RW, White LR. (1978). Electrophoretic mobility of a spherical colloidal particle. J Chem Soc Faraday Trans, 2, 1607-1626.
31. Page ME, Pinto-Alphandary H, Chachaty E, Andremont A, Couvreur P. (1996). Entrapment of colistin into polyhexylcyanoacrylate nanoparticles: preparation, drug release and tissue distribution in mice. STP Pharma Sci, 6, 298-301.
32. Peracchia MT, Vauthier C, Popa M, Puisieux F, Couvreur P. (1997). Investigation of the formation of sterically stabilized poly(ethylene glycol/isobutylcyanoacrylate) nanoparticles by chemical grafting of polyethylene glycol during the polymerization of isobutyl cyanoacrylate. STP Pharma Sci, 7, 513-520.
33. Plunkett W, Huang P, Gandhi V. (1995). Preclinical characteristics of gemcitabine. Anticancer Drugs, 6, 7-13. (Pubitemid 26014890)
34. Reddy LH, Murthy RSR. (2004). Pharmacokinetics and biodistribution studies of doxorubicin loaded poly(butyl cyanoacrylate)nanoparticles synthesized by two different techniques. Biomed Papers, 148, 161-166.
35. Reddy LH, Couvreur P. (2008). Novel approaches to deliver gemcitabine to cancers. Curr Pharm Design, 14, 1124-1137. (Pubitemid 351982559)
36. Simeonova M, Chorbadjiev K, Antcheva M. (1998). Study of the effect of polybutylcyanoacrylate nanoparticles and their metabolites on the primary immune response in mice to sheep red blood cells. Biomaterials, 19, 2187-2193. (Pubitemid 28550374)
37. Stella B, Arpicco S, Rocco F, Marsaud V, Renoir JM, Cattel L, Couvreur P. (2007). Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules. Int J Pharm, 344, 71-77. (Pubitemid 47464827)
38. Storniolo AM, Allerheiligen SRB, Pearce HL. (1997). Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 24, S7-2-S7-7.
39. van Oss CJ. (2006). Contact angle and surface tension determination and preparation of solid surfaces. In: Interfacial Forces in Aqueous Media, van Oss, CJ (2nd ed., pp. 131-156). Boca Raton, FL: CRC Press.
40. Vauthier C, Dubernet C, Chauvierre C, Brigger I, Couvreur P. (2003a). Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J Control Release, 93,151-160. (Pubitemid 37421357)
41. Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H, Couvreur P. (2003b). Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev, 55, 519-548. (Pubitemid 36423302)
42. Verdun C, Brasseur F, Vranckx H, Couvreur P, Roland M. (1990). Tissue distribution of doxorubicin associated with polyhexylcyanoacrylate nanoparticles. Cancer Chemother Pharmacol, 26, 13-18. (Pubitemid 20122882)
43. Veronese SM, Maisano C, Scibilia J. (1995). Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer. Anticancer Res, 15, 2717-2722. (Pubitemid 26095087)